18 February 2025 - Biocon announced today that the European Commission granted marketing authorisation in the European Union for Yesintek, ...
19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
19 February 2025 - NICE has published final evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin ...
18 February 2025 - These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review ...
18 February 2025 - FDA decision expected by 18 August 2025. ...
18 February 2025 - Welireg is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union ...
18 February 2025 - This marks the second breakthrough therapy designation for petosemtamab in head and neck squamous cell carcinoma. ...
18 February 2025 - FDA to review applications under priority review, with a PDUFA date of 19 June 2025. ...
18 February 2025 - PDUFA target action date of 18 August 2025. ...
5 February 2025 - The medicine is already approved in the UK to treat advanced cases of the disease. ...
18 February 2025 - If approved, Dupixent would be the first and only targeted medicine to treat bullous pemphigoid in the US; ...
17 February 2025 - This national approval was granted after an Access Consortium new active substance work-sharing initiative (NASWSI) procedure. ...
17 February 2025 - Second fast track designation following brain cancer approval. ...
17 February 2025 - For some medical conditions, including conditions without effective treatments, multiple promising but unproven therapies may exist, with ...
17 February 2025 - Innovent Biologics announced that its first in class PD-1/IL-2α-bias bi-specific antibody fusion protein, IBI363, has received its ...